Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Depe...
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer
Subjects
More information
Scope and Contents
Contents
Infliximab (IFX) or adalimumab (ADA) use in patients with inflammatory bowel disease (IBD) leads to increased risk of tuberculosis (TB). This meta-analysis evaluated the factors which determine this risk, with special focus on local TB incidence.
All studies until January 31, 2019, which reported the development of TB in patients with IBD on IFX...
Alternative Titles
Full title
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2352646834
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2352646834
Other Identifiers
ISSN
0002-9270
E-ISSN
1572-0241
DOI
10.14309/ajg.0000000000000527
